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Tuberculosis (TB) is a major global health problem and there is a dire need for an
improved treatment. A strategy to combine vaccination with drug treatment, termed
therapeutic vaccination, is expected to provide benefit in shortening treatment duration
and augmenting treatment success rate. RUTI candidate vaccine has been specifically
developed as a therapeutic vaccine for TB. The vaccine is shown to reduce bacillary
load when administered after chemotherapy in murine and guinea pig models, and is
also immunogenic when given to healthy adults and individuals with latent TB. In the
absence of a validated correlate of vaccine-induced protection for TB vaccine testing,
mycobacterial growth inhibition assay (MGIA) has been developed as a comprehensive
tool to evaluate vaccine potency ex vivo. In this study, we investigated the potential of
RUTI vaccine to control mycobacterial growth ex vivo and demonstrated the capacity of
MGIA to aid the identification of essential immune mechanism. We found an association
between the peak response of vaccine-induced growth inhibition and a shift in monocyte
phenotype following RUTI vaccination in healthy mice. The vaccination significantly
increased the frequency of non-classical Ly6C− monocytes in the spleen after two doses
of RUTI. Furthermore, mRNA expressions of Ly6C−-related transcripts (Nr4a1, Itgax,
Pparg, Bcl2) were upregulated at the peak vaccine response. This is the first time the
impact of RUTI has been assessed on monocyte phenotype. Given that non-classical
Ly6C− monocytes are considered to play an anti-inflammatory role, our findings in
conjunction with previous studies have demonstrated that RUTI could induce a balanced
immune response, promoting an effective cell-mediated response whilst at the same time
limiting excessive inflammation. On the other hand, the impact of RUTI on non-classical
monocytes could also reflect its impact on trained innate immunity which warrants
further investigation. In summary, we have demonstrated a novel mechanism of action
of the RUTI vaccine, which suggests the importance of a balanced M1/M2 monocyte
function in controlling mycobacterial infection. The MGIA could be used as a screening
tool for therapeutic TB vaccine candidates and may aid the development of therapeutic
vaccination regimens for TB in the near future.
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INTRODUCTION
Tuberculosis (TB) remains a leading cause of death from
infectious disease and is responsible for an estimated annual
1.6 million deaths globally (1). With the emergence of drug-
resistant TB, there is a dire need for new therapy and for shorter,
more effective, safer, and better tolerated treatment regimens.
Therapeutic vaccination, which is a strategy to combine
vaccination with drug treatment, could help to achieve these
objectives and improve current treatments (2). TB vaccines are
regarded to be equally effective against drug-sensitive and drug-
resistant strains, due to the nature of drug-resistant mutations
which are not considered to change the immunological profile of
the organism (3). Therapeutic vaccination was first introduced
by Robert Koch in his initial attempts to administer tuberculin
to TB patients (4), and currently several therapeutic TB vaccine
candidates are available in the vaccine pipeline.
The RUTI vaccine is among the few candidates currently
on the clinical pipeline which is specifically developed as
a therapeutic TB vaccine. The vaccine is composed of
purified and liposomal cellular fragments of Mycobacterium
tuberculosis (Mtb) bacilli cultured under stress (to mimic intra-
granulomatous conditions) to induce latency antigens which
would typically be hidden from the immune system (5). The
immune response to RUTI has been studied in animal models
and clinical studies and is characterized by a poly-antigenic
response. Its main immunotherapeutic effect is thought to be
through induction of a T helper-1 (Th1) response, not only
against growth-related antigens but also structural antigens as
shown in the murine model (2, 6). The prophylactic capacity of
RUTI vaccine has also been evaluated in a murine model and
the vaccination significantly reduced bacterial counts in both
lungs and spleens following challenge with virulent bacilli (7).
RUTI vaccination generated a poly-antigenic response in healthy
human volunteers (phase I study), as well as in HIV-positive and
HIV-negative patients with latent TB after isoniazid treatment for
1 month in a phase II clinical trial (8, 9).
The lack of an immune correlate of protection has been
hampering the development of novel TB vaccines, as lengthy
and expensive clinical trials with protracted follow-up periods
are needed to demonstrate efficacy and proceed to licensure (10).
For a single vaccine candidate, it generally takes at least a decade
to reach efficacy trials from discovery (3, 10). If we are going to
achieve the WHO target to eliminate TB by 2050, major progress
is required to overcome the painstakingly slow progress. Such
an immune correlate could also be used to help identify vaccine
candidates with the greatest potential efficacy.
Mycobacterial growth inhibition assay (MGIA) has been
developed as a simple and comprehensive tool to evaluate
vaccine immunogenicity ex vivo (11, 12). As an assay that
measures the summative vaccine-mediated host capacity to
control mycobacterial growth, the MGIA is proposed as a
screening tool for TB vaccine candidates (13–15). The nature
of the ex vivo assay does not require that the vaccine-mediated
immunemechanismwhich underlies growth control to be known
in advance, while in turn the MGIA could help to determine
immune mechanisms of protection through investigation of the
cellular frequencies, phenotypes and cytokines that associate
with enhanced growth inhibition (16–18). Several variations of
human and murine MGIAs have been described in the literature
[reviewed in (12)]. Here, we implemented the assay using direct
co-culture of mouse splenocytes with mycobacteria, based on a
recent optimization work (15), to investigate the potential of the
RUTI vaccine to control mycobacterial growth ex vivo.
Monocytes are highly plastic and heterogeneous circulating
cells, which are known to change their functional phenotype in
response to environmental stimulation (19, 20). Two distinct
subpopulations of mouse monocytes have been identified,
commonly referred to as Ly6C+ and Ly6C− monocytes (21).
Ly6C+ monocytes represent classical pro-inflammatory and
phagocytic monocytes which could subsequently differentiate
into M1 macrophages, while Ly6C− monocytes are regarded
as non-classical anti-inflammatory monocytes which could
differentiate into M2 macrophages (19). In addition to the
induction of an antigen-specific Th1 response, evidence suggests
the potential importance of a balanced M1/M2 monocyte
function in controlling mycobacterial infection (20, 22). In
a previous murine study, the RUTI vaccine was shown to
reduce intragranulomatous infiltration and decrease Tumor
Necrosis Factor (TNF)-α expression in Mtb infected mice (6).
We hypothesize that immunization with RUTI would lead to
improved control of mycobacterial growth ex vivo and such
observation could be used to gain insight into the mechanism of
immune protection.
In this study, we investigated the impact of RUTI vaccination
in mice using the ex vivo MGIA assay and found an association
between peak response of vaccine-induced growth inhibition
and a shift in monocyte phenotype. Our study demonstrates the
benefit of the ex vivo MGIA to aid the identification of immune
mechanisms of action for therapeutic TB vaccine candidates.
The MGIA could be used as a tool for screening such vaccine
candidates and might aid the development of therapeutic vaccine
regimens for TB patients.
MATERIALS AND METHODS
Animals
Six to seven week-old female C57Bl/6 mice (Charles River, UK)
acclimatized for at least 5 days were housed and handled in the
Biological Services Facility (BSF) at London School of Hygiene
and Tropical Medicine (LSHTM), UK. Mice were provided
standard sterilized food and water ad libitum. Animals were
housed in specific pathogen-free individually vented cages with
environmental enrichment, with equal day and light cycle, at
temperature between 19◦-23◦C and relative humidity of 45–
65%. Mice were allocated to cages as groups of six. All animal
work was carried out in accordance with the Animals (Scientific
Procedures) Act 1986 under a license granted by the UK Home
Office (PPL 70/8043), and approved locally by the LSHTM
Animal Welfare and Ethics Review Body.
Immunization
Seven experimental groups were established, with six mice per
group (Figure 1). Mice in the treatment groups were vaccinated
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FIGURE 1 | Experimental design and vaccination schedule. As indicated in the figure, orange arrows mean RUTI vaccination (dotted if boosting). The purple X
represents endpoint (mice sacrifice). Enzyme-linked immunospot assay and mycobacterial growth inhibition assay were performed at each endpoint. In total, 42 mice
were sacrificed at all time points (6 mice per group).
with RUTI, which is based on purified fragments of Mtb
cultured under stress conditions and liposomed, manufactured
by Archivel Farma (Badalona, Catalonia, Spain). Vaccination
with RUTI (batch A14, 204 µg) was performed subcutaneously
once or twice (3 weeks apart), as has been performed previously
(6, 7). Five groups of mice were vaccinated with RUTI at week
0, among which three groups were boosted at week 3. Mice were
sacrificed at week 1, 3, 4, 6, and 9 as the designated time points
of this experiment. Two groups of mice sacrificed at week 1 and
6 served as naïve controls.
Mycobacteria and Culture Conditions
Bacillus Calmette-Guérin (BCG) Pasteur strain was obtained
from Aeras (Rockville, MD, USA) as frozen aliquots. These were
stored at −80◦C until needed. Mycobacterial suspensions for
infection inoculum and BACTECMGIT standards were prepared
in antibiotic-free media (described below). All work with cells
pre-BCG infection and involving BCG infected samples were
performed in Biosafety Level (BSL) 2 laboratory.
Ex vivo Mycobacterial Growth Inhibition
Assay (MGIA)
At the determined time points, spleens were removed aseptically
from mice and single splenocyte suspensions were prepared
by homogenization through 100µm cell strainers followed by
lysis of red blood cells and washing. Cells were adjusted to 5
× 106 splenocytes per 300 µl in antibiotic-free media [RPMI-
1640 (Sigma-Aldrich, Dorset, UK) + 10% heat-inactivated FBS
(Labtech International Ltd, Uckfield, UK) + 2mM L-Glutamine
(Fisher Scientific, Loughborough, UK)]. Mycobacteria were
diluted in sufficient volume for all samples in the same media to
a concentration of 90 CFU per 300µl. Three hundred microliters
aliquots of bacteria were added to the splenocytes, and the
splenocytes-mycobacteria co-culture (600µl) was then incubated
in 48-well plates (Sigma-Aldrich, UK) at 37◦C for 4 days.
After 4 days, splenocytes-mycobacteria mixtures were
collected from the 48-well plates by pipetting up and down three
times before transferring to 2ml screw cap tubes. The tubes
were centrifuged at 12,000 rpm in a bench top micro centrifuge
and the supernatants were removed (500 µl) while ensuring
the pellets remain intact. Five hundred microliters sterile tissue
culture grade water was added to the 48-well plates which were
incubated at room temperature for 5min, followed by pipetting
up and down for five times before transferring to the 2ml screw
cap tubes with pellets. The pellets were dissolved by pipetting
and lysates containing mycobacteria were transferred to Bactec
MGIT tubes supplemented with PANTA antibiotic and oleic
acid-albumin-dextrose-catalase (OADC) enrichment broth [all
from Becton Dickinson (BD), Oxford, UK]. The MGIT tubes
were incubated in a Bactec MGIT liquid culture system (BD)
until registered positive. The resulting time to positivity (TTP)
was converted to bacterial numbers (log10 CFU) using a standard
curve. The standard curve was obtained by a linear regression
analysis of TTP values from inoculated BCG in 10-fold dilutions
against CFUs obtained from plating aliquots of BCG onto 7H11
agar plates containing 10% OADC supplement (Yorlab, York,
UK) and 0.5% glycerol. Direct-to-MGIT controls were included
at each time point, defined as 90 CFU BCG directly placed into
Bactec MGIT system without any pre-incubation (at day 0). To
compare the growth inhibition between time points, log10 CFU
values were normalized using the direct-to-MGIT controls by
subtracting or adding the values based on the average TTP of
direct-to-MGIT controls.
Interferon (IFN)-γ ELISpot
To measure antigen-specific response toward mycobacterial
antigen following RUTI vaccination over the time course, IFN-
γ ELISpot assay was performed. Single cell suspensions of mouse
splenocytes were resuspended in RPMI-1640 media containing
10% heat-inactivated FBS and 2mM L-Glutamine. 96-well
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microtiter ELISpot plates (MAIPS4510, Millipore, Watford, UK)
were coated with 10µg/ml rat anti-mouse IFN-γ (clone AN18,
Mabtech, Nacka Strand, Sweden). Free binding sites were blocked
with the above mentioned media. 2.5 × 105 of total splenocytes
were added and incubated in duplicate with 10µg/ml Purified
protein derivative (PPD) (Oxford Biosystem, Oxfordshire, UK),
RPMI media as a negative control, or phytohemaglutinin
(PHA) (1µg/ml, Sigma-Aldrich) and phorbol myristate acetate
(PMA) (0.1µg/ml, Sigma-Aldrich) as a positive control. Cells
were incubated overnight at 37◦C with 5% CO2. IFN-γ was
detected with 1µg/ml biotin labeled rat anti-mouse antibody
(clone R4-6A2, Mabtech) and 1µg/ml alkaline phosphatase-
conjugated streptavidin (Mabtech). The enzyme reaction was
developed with BCIP/NBT substrate (5-Bromo-4-chloro-3-
indolyl phosphate/Nitro blue tetrazolium) (MP Biochemicals,
UK) and stopped by washing the plates with tap water when
individual spots could be visually detected (up to 3min). Upon
completion of the color development stage, spots were quantified
using an automated plate reader with ELISpot 5.0 software. IFN-
γ-specific cells are expressed as number of spot forming cells
(SFC) per million splenocytes after non-specific background was
subtracted using negative control wells.
Flow Cytometry
Single splenocyte suspensions were fixed and red blood cells
were lysed using PhosFlow lyse-fix solution (Becton Dickinson,
Oxford, UK) for 30min at 4◦C prior to freezing. Fixed cells
were then re-suspended in freezing media (FBS containing 10%
DMSO) at the concentration of 106 cells per ml and stored in a
−40
◦
C freezer from each time point. Frozen cells were thawed
by adding FACS buffer (PBS containing 5% FBS) and pipetting
up and down to encourage thawing. Cells were added to 10ml
of FACS buffer and centrifuged for 10min at 1,800 rpm. Cells
were re-suspended in FACS buffer (concentration 107 cells/ml)
and were left for 15min on ice for rehydration.
Fc block (anti-mouse CD16/32, eBioscience, Loughborough,
UK) was added to cells and left for further 10min on ice prior
to surface staining. Cells were aliquoted in FACS tubes (100 µl
each, 106 cells) and stained with the following titrated antibody:
1.25 µl CD3-APC/Cy7 (clone 17A2), 2.5 µl CD45R/B220-BV510
(clone RA3-6B2), 1.25 µl CD11b-PerCP/Cy5.5 (clone M1/70),
2.5 µl Ly6G-BV711 (clone 1A8), and 5 µl Ly6C-BV421 (clone
HK1.4). All antibodies were purchased from Biolegend (via
Fisher Scientific).
Cells were incubated for 30min at RT in the dark and washed
prior to analysis. Fluorescence minus one (FMO) controls were
set using cells for each antibody and used to guide gating.
OneComp beads (eBioscience, Loughborough, UK) were used to
calculate compensation by staining with single antibodies as per
manufacturer’s instruction. Cells were acquired on a BD LSR II
flow cytometer. Data was analyzed with FlowJo software version
10.4 (Treestar Inc., USA).
Real-Time Quantitative PCR
To quantitatively analyse the mRNA expressions in splenocytes
following RUTI vaccination, real-time quantitative reverse
transcriptase PCR (qRT-PCR) assays were performed. 5 ×
105 splenocytes were stimulated overnight with PPD (final
concentration 10µg/ml). Cells were pelleted, lysed in 200 µl
RLT buffer containing 10 µl/ml β-mercaptoethanol and stored in
−40
◦
C freezer from each time point. Cells were thawed and RNA
was extracted using the RNAeasy mini kit (Qiagen, Manchester,
UK) according to the manufacturer’s instructions. After a
DNAse treatment with RNase-free DNAse set (Qiagen, UK),
total RNA concentration was determined by spectrophotometry
with a Nanodrop (Labtech International, Heathfield, UK). One
microgram of each sample of total RNA was reverse-transcribed
into complementary DNA (cDNA) using Omniscript R© Reverse
Transcription kit (Qiagen, UK) according to the manufacturer’s
recommendation, using oligo(dT) (Invitrogen, UK) to obtain
cDNA. Each PCR was carried out in a 20 µl volume in the
presence of 10 µl of 2x QuantiTect SYBR Green PCR Master
Mix (Qiagen, UK), 1 µl of cDNA (or water as a negative control),
MgCl2 to a final concentration of 2.5mM and primers to a final
concentration of 0.5µM. PCR was carried out for 10min at
95◦C denaturation, followed by 40 cycles at 95◦C for 15 s, and
60◦C for 1min in Applied Biosystems 7500 (Applied Biosystems,
CA, USA).
Analyses were performed for gene expressions of Nr4a1,
Cebpb, Itgax, Pparg, Bcl2 (markers of Ly6C−), Ccr2, Sell, Ly6C2
(markers of Ly6C+), and β-actin (housekeeping gene). Primers
used were listed in Table S1. mRNA expression of β-actin was
quantified for every target sample to normalize for efficiency in
cDNA synthesis and RNA loading. A ratio based on the β-actin
mRNA expression was obtained for each sample.
Statistical Analysis
Statistical analysis was carried out using GraphPad Prism version
7 (GraphPad, La Jolla, CA, USA). A p-value of < 0.05 was
considered statistically significant. The specific tests used for each
analysis are described in the figure legends.
RESULTS
RUTI Vaccination Did Not Induce
Antigen-Specific IFN-γ but Did Improve
Mycobacterial Growth Inhibition in
Murine Splenocytes
To assess the immune response to mycobacterial antigens
from mice vaccinated with RUTI, splenocytes were stimulated
with PPD and the number of IFN-γ-producing cells was
measured using the ELISpot assay (Figure 2, red line).
We found a weak, non-significant response at 1 week
following the second vaccination with RUTI (week 4, p =
0.08). This response appeared to have decreased by week 6.
Significant control of mycobacterial growth was observed
1 week after the first vaccination and 3 weeks after the
second RUTI vaccination (week 6) when compared to the
baseline control (p = 0.0214, Figure 2, blue line). A trend
of reduction was still observed 6 weeks after the second
vaccination (week 9), although it did not reach significance
(p= 0.064).
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FIGURE 2 | ELISpot (Red Line). IFN-γ response in mice receiving vaccination with RUTI was measured. Modest PPD antigen-specific responses were detected in
splenocytes of healthy C57BL/6 mice across time points. The splenocytes were stimulated overnight with PPD, and the responses were detected using the IFN-γ
ELISpot assay. SFC, spot-forming cells. Dark red line indicates mean response, and shading indicates range. Statistical significance was tested using Mann-Whitney
test. MGIA (Blue Line). RUTI vaccination induced mycobacterial growth inhibition in murine splenocytes, performed ex vivo in a 48-well plate. Dark blue line indicates
mean mycobacterial growth, and shading indicates range. Time point 0 represents unvaccinated naïve-control mice sacrificed at week 1. One-way ANOVA was used
to test for significance, followed by t-test. *p < 0.05; **p < 0.01.
In a separate experiment performed in rotating tubes instead
of 48-well plates (Figure S1A in SupplementaryMaterial), RUTI-
induced control of mycobacterial growth was superior to BCG-
induced control when both vaccines were given 6 weeks prior
to sacrifice (p < 0.005, Figure S1B). Therefore, week 6 appeared
to be the peak response of RUTI in the ex vivo MGIA
system. Growth control was also significant when compared
to an age-matched control group (p < 0.05, Figure S2A
in Supplementary Material).
RUTI vaccination led to control of mycobacterial growth
as measured by the MGIA, despite a weak, non-significant
antigen-specific IFN-γ response. This was consistent with results
of a separate experiment with RUTI and BCG, in which
BCG induced IFN-γ-secreting cells whereas RUTI did not and
yet cells from RUTI immunized mice were better able to
control mycobacterial growth than cells from BCG vaccinated
mice (Figures S1C,D in Supplementary Material). The lack of
robust IFN-γ response following two doses of RUTI in healthy
mice has been observed previously during potency testing
for batch release (Archivel Farma, personal communication).
Then, four doses of RUTI were required for induction of
a detectable IFN-γ response. Although IFN-γ is associated
with control of TB infection in mice and reduces the risk of
TB disease in humans (23–25), some studies suggested IFN-
γ alone was not sufficient (26, 27). As the MGIA measures
the summative effect of immune responses from all cellular
components, our data implied an alternative mechanism by
which growth inhibition could be enhanced ex vivo following
RUTI vaccination.
Shift of Monocyte Phenotype Following
RUTI Vaccination in Healthy
Mouse Splenocytes
In this experiment, we investigated the impact of RUTI
vaccination on the population of immune cells in the spleen
using flow cytometry (Figure 3 and Figure S3 in Supplementary
Material). RUTI did not appear to alter the percentages of
monocytes/macrophages, T-cells, and B-cells in the spleen
of healthy mice (p > 0.05, Figures S3A,C,D). We also
measured monocyte to lymphocyte (ML) ratio as a factor
influencing mycobacterial growth inhibition (28, 29), defined
as the percentage of monocytes/macrophages divided by the
percentage of T-cells and B-cells. We did not find a significant
change of ML ratio following RUTI vaccination across time
(Figure S3B).
We then further characterized monocyte phenotype based
on the Ly6C marker, and observed a significant increase of
Ly6C− monocytes/macrophages (non-classical) at weeks 3, 6,
and 9 following RUTI vaccination (p < 0.05, Figure 3B).
The peak increase of Ly6C− cells was observed at week
6, with the shift being evident compared to both baseline
and age-matched naïve control at week 6 (Figure S2B in
Supplementary Material). The Ly6C+ monocytes/macrophages
(classical) population appeared to be decreasing following
vaccination, although there was an initial significant increase
observed at week 1 (p < 0.05, Figure 3). The shift of
Ly6C+/Ly6C− phenotype at week 6 was notably consistent
with the peak response of the ex vivo mycobacterial growth
inhibition assay, in which enhanced inhibition was observed
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FIGURE 3 | The shift of Ly6C+ and Ly6C− monocytes/macrophages populations following RUTI vaccination in healthy mice. (A) Gating strategy for flow cytometric
analysis. Splenocytes from C57BL/6 mice were fixed, stained and data acquired as described in Materials and Methods. Cell debris was gated out by use of
FSC-SSC gate, followed by gating on single cells (FSC-A and FSC-H). A sequential gating strategy was then applied to determine the frequency of T-cells (CD3+), B
cells (B220+), monocytes/macrophages (CD11b+ Ly6G− ssclow), and the phenotypes of the monocytes/macrophages (Ly6C+ or Ly6C−) as a percentage of live
cells. Plots shown are from a sample of a C57BL/6 spleen. (B) The frequencies of Ly6C+ and Ly6C− monocytes/macrophages were compared at each time point
following RUTI vaccination. Dark brown and dark purple lines represent mean percentages of Ly6C+ and Ly6C− monocytes/macrophages, respectively and shading
indicates range. Time point 0 represents unvaccinated naïve-control mice sacrificed at week 1. Statistical significance was tested using unpaired t-test, *p < 0.05;
**p < 0.01; ***p < 0.005.
following two doses of RUTI vaccination. We found a non-
significant correlation between higher frequency of Ly6C−
monocytes/macrophages and lower growth of mycobacteria
across time points (p = 0.247, Spearman r = −0.20, data
not shown).
Gene Expression of Ly6C+- and Ly6C−-
Related Markers Induced by
RUTI Vaccination
To confirm findings from the flow cytometry analysis described
in the previous section, we performed real-time qRT-PCR
looking at transcripts associated with Ly6C+ and Ly6C−
monocytes/macrophages. The selection of transcripts was based
on a recent publication by Mildner et al. (21) regarding genomic
characterization of murine monocytes. We chose differentially
expressed transcripts between the two monocyte subsets
from several gene clusters of monocyte development. Three
transcripts, namely Nr4a1, Itgax, and Pparg, were selected from
a cluster which was strongly upregulated in Ly6C− compared
to Ly6C+ monocytes. Cebpb was selected from a cluster that
showed a gradual increase of expression from Ly6C+ to Ly6C−
monocytes. Bcl2 belongs to a cluster characterized by transcripts
associated with a progenitor phenotype of MDP (monocyte-
macrophage DC progenitor), which was highly expressed in
Ly6C− monocytes. In addition, transcripts associated with
Ly6C+ monocytes were selected from clusters involved in
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cell cycle (Sell and Ly6C2) as well as maturation of Ly6C+
monocytes (Ccr2).
The mRNA expressions of Ly6C−-related transcripts,
including Nr4a1, Itgax, Pparg, Bcl2, were significantly
upregulated following the second RUTI vaccination at week
6 (p < 0.05, Figures 4A,C–E), with a trend of upregulation
for Cebpb (p = 0.136, Figure 4B). While we did not observe
a difference in expression of Ccr2, a Ly6C+ -related gene,
following RUTI vaccination at the peak time point, we saw
significant upregulations of Sell and Ly6C2 at week 6 (p < 0.05,
Figures 4G–H).
DISCUSSION
Vaccination with RUTI resulted in enhanced control of
mycobacterial growth, notably at 3 weeks following the second
vaccination (week 6), which was considered as the peak response
of the vaccine observed in the ex vivo assay system. In addition,
there was also a significant reduction of mycobacterial growth
at 1 week after the first vaccination. There was no significant
induction of antigen-specific IFN-γ as measured by ELISpot
or ELISA. These observations were replicated in a separate
experiment and support the notion that the MGIA measures
different aspects of immunity following vaccination as compared
to the IFN-γ-based assay, with the MGIA being reflective
of the summative effect of host immune responses at the
point of tissue harvest, compared to the IFN-γ-based assay
which is an assessment of a T-cell mediated recall response
following vaccination.
In this context, we argue that the ex vivo assay is more
capable of measuring the direct, short-term effect of vaccination,
while the IFN-γ response is more representative of the medium-
to long-term protection conferred by vaccination. This was
supported by a recent finding of Fletcher et al. in which antigen-
specific IFN-γ response was associated with reduced risk of
developing TB disease in BCG-vaccinated South African infants
(25). In testing therapeutic vaccine candidates, it might be more
relevant to measure the direct effect of vaccination, as it would
represent the immediate and potentially synergistic impact of a
vaccine during TB chemotherapy. This was depicted in the ex
vivo assay, in which significant mycobacterial growth inhibition
was observed at 1 week following the first RUTI vaccination,
when there was no apparent increase of IFN-γ response at this
time point.
The ex vivo MGIA was shown to be able to capture the
impact of distinct aspects of protective immunity as a part
of a summative measurement of cellular immune responses.
In this study, we used BGC as the immune target of the
growth inhibition assay, as previous studies have shown a good
concordance of growth between BCG andMtb in theMGIA assay
when both mycobacteria were used to assess responses following
vaccination and treatment (30–32). In addition, studies by
Marsay et al. and Zelmer et al. also showed that the ex vivo growth
inhibition using BCG as immune target was correlated with in
vivo growth in mouse challenge experiment using Mtb Erdman
(15, 16). In our experiment, we performed flow cytometry to
characterize immune cells associated with enhanced growth
inhibition across time. RNA was also isolated to investigate
gene expression by RT-qPCR. The important finding in our
present study was the impact of RUTI vaccination in shifting
the phenotype of Ly6C+/Ly6C− monocytes/macrophages in the
spleen of healthy mice. This was the first time the impact of
RUTI on monocyte phenotype has been assessed. In addition,
while others have shown a lack of correlation between antigen-
specific IFN-γ and mycobacterial growth inhibition, this is the
first demonstration of vaccine induced mycobacterial growth
inhibition in the absence of antigen-specific IFN-γ. Our results
suggest that the enhanced control of mycobacterial growth ex
vivo was associated with the increase of Ly6C− monocytes (non-
classical, anti-inflammatory), which were both observed 3 weeks
after the second vaccination with RUTI (week 6).
We confirmed the flow cytometry finding by demonstrating
the upregulation of transcripts associated with Ly6C− cells at
the peak time point (week 6), while one of the Ly6C+ gene
transcript (Ccr2) remained unchanged. Among the significantly
upregulated transcripts in our study was Nr4a1, which is
obligatory for Ly6C− monocytes development (33). Expression
of Nr4a1 as a monocyte survival factor is regulated by Cebpb
(21, 34), which was also elevated following RUTI vaccination.
In addition, the expressions of all other Ly6C−-associated
transcripts (Itgax, Pparg, Bcl2) were significantly upregulated
following vaccination in our study. As Ly6C− monocytes are
known to mature from Ly6C+ (35, 36), the increased expression
of some Ly6C+ transcripts (Sell and Ly6C2) at the peak time
point was regarded as a vestige of the transition from Ly6C+
to Ly6C−. Ly6C− monocytes do not represent a distinct lineage
and instead arise from the conversion of Ly6C+ cells (37) and
approximately 92% of expressed transcripts are shared between
the two monocyte subsets (38). Our results suggest that RUTI
could enhance Ly6C+ cell frequency and induce maturation of
Ly6C+ to Ly6C− monocytes. This was evidenced by our results
in which an initial increase of Ly6C+ monocytes was observed
at week 1 following the first RUTI vaccination, followed by the
shift toward Ly6C− and the decrease of Ly6C+ monocytes at the
subsequent time points.
Ly6C− monocytes secrete anti-inflammatory cytokine upon
bacterial infection in vivo and when recruited to tissue, are
more likely to differentiate into M2 macrophages (35). This
is in contrast to Ly6C+ monocytes, which are more likely
to mature into pro-inflammatory M1 macrophages (36). In
relation to our findings, the study by Guirado et al. (6)
demonstrated a decrease of intragranulomatous infiltration in
the lungs upon administration of RUTI in infected mice after
treatment. One of the notable findings in that study was
a significant decrease of TNF-α at the earliest time point
after RUTI administration, measured by mRNA expression in
the lung. Among the producers of TNF-α during bacterial
infection are Ly6C+ monocytes which will subsequently
differentiate into M1 macrophages (19, 39). Although our
experiment differs with the one previously performed by
Guirado and colleagues in several aspects (including the
investigated target organ), the decrease of TNF-α observed in
the previous study could be associated with the impact of
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FIGURE 4 | mRNA expressions of Ly6C− -related (A–E) and Ly6C+ -related genes (F–H) in mice following vaccination with RUTI at week 6 compared to the
age-matched naïve control group. Data are expressed as ratio obtained after dividing every value by the expression of β-actin in each sample and multiplying it by a
factor (ranging from 101 to 103). The box plots show the minimum and maximum values (ends of the whiskers), the median (band near the middle of the box) and
interquartile ranges. Statistical significance was tested using unpaired t-test, *p < 0.05; **p < 0.01; ***p < 0.005.
RUTI on monocyte populations which has been discovered in
our investigation.
RUTI is a poly-antigenic vaccine made from fragmented
Mtb bacilli designed to induce host immune response against
latency epitopes, which is grown in stress, purified and
liposomed. The part of RUTI formulation that could potentially
influence monocyte phenotype remains to be further explored.
Nevertheless, our study has revealed an interesting mechanism
of action of RUTI as a therapeutic vaccine for TB. As reviewed
by Prabowo et al. (40), it is essential to prevent the occurrence
of exacerbated immune response for a successful therapeutic
vaccination strategy in TB. This was exemplified in a recent study,
in which an excessive inflammation from the T-cell compartment
could also be deleterious in TB (41). The fact that RUTI
vaccination could induce a shift toward an anti-inflammatory
monocyte phenotype might be considered as an advantage in
this context and such approach should be further investigated in
future studies.
While this could imply that less inflammation might be
beneficial for the ex vivo control of mycobacterial growth
following RUTI vaccination in healthy mice, our results
should be interpreted with prudence in relation to previous
results of RUTI testing in in vivo animal models. The
observed trend of correlation between the frequency of Ly6C−
monocytes/macrophages and growth ofmycobacteria across time
points hinted that this was only one aspect contributing to the
enhanced ex vivo growth control and other factors might be
playing roles. In a murine model infected with Mtb, RUTI has
been shown to trigger a balanced Th1/Th2 response as well
as Immunoglobulin (Ig)G1, IgG2a and IgG3 antibodies against
13 Mtb antigens, reflecting its broad immunogenicity (42). In
addition, the vaccine was also shown to induce a Th3 response
as a subset population of regulatory T-cells (42). In another
mouse study, RUTI administration following drug therapy in
infected mice stimulated stronger IFN-γ secretion by CD4+
and CD8+ T-cells compared to BCG against early secretory
antigen target (ESAT)-6, Ag85B, and PPD and also induced an
immune response against structural antigens Ag16 kDa and Ag38
kDa (6). While immune responses in infected and drug-treated
mice could be reasonably different in comparison to healthy
mice as was done in our ex vivo study, the fact that RUTI did
not induce an exacerbated immune response in various animal
studies could be linked to its impact on Ly6C− monocytes which
was discovered in our investigation. In the experimental animals
immunized with RUTI, no elevated IgE levels were observed (43).
In this study, histology also revealed no eosinophilia, necrosis or
granulomatous infiltration, as well as allergic or hypersensitivity
reactions. Taken together, these findings and observations suggest
that RUTI could induce a balanced immune response, promoting
an effective cell-mediated response whilst at the same time
limiting an excessive inflammation, which could be beneficial for
its implementation as a therapeutic vaccine for active TB patients
undergoing treatment.
Intriguingly, a recent study by Joosten et al. demonstrated the
protective effect of human non-classical CD14dim monocytes in
inhibiting mycobacterial growth following recent Mtb exposure
and BCG vaccination through the trained innate immunity
mechanism (44). As Ly6C− monocyte is the equivalent of
CD14dim monocyte in mouse (19), our results could also suggest
an impact of RUTI on trained innate immunity which has not
been characterized before. BCG is known to induce trained
immunity on human monocytes and such ability has been
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attributed to the non-specific protective effect conferred by the
vaccine (45, 46). A synthetic mycobacterial structure—muramyl
tripeptide (MTP)—is also considered to induce trained immunity
(47), and interestingly, both MTP and RUTI are delivered in
liposome. Further studies are required to elucidate downstream
and upstream pathways related to the potential effect of RUTI on
trained innate immunity.
In summary, we have demonstrated the benefit of the ex
vivo MGIA assay to help streamlining and identifying immune
mechanisms of a therapeutic TB vaccine candidate. Our results
could be complemented by further experiments, such as by using
cells from infected mice. Depleting Ly6C− monocytes and using
genetically deficient mice could also provide more insight into
the mechanism of protection by Ly6C− monocytes in the ex
vivo assay system. Future investigation of the novel immune
mechanism of RUTI observed in our study is also warranted
in upcoming clinical trials of the vaccine and could potentially
accelerate the development of a therapeutic vaccine regimen for
TB patients in the near horizon.
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